Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
Caroline Imbert, Anne Montfort, Marine Fraisse, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Zhengyi Wang, Xiaoying Wu
Cancer Medicine (2020) Vol. 9, Iss. 21, pp. 8086-8121
Open Access | Times Cited: 142
The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment
Maximilian Haist, Henner Stege, Stephan Grabbe, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 210-210
Open Access | Times Cited: 137
The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment
Yanghong Ni, Xiaoting Zhou, Jia Yang, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 104
BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer
Beibei Liu, Xinhua Liu, Lulu Han, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 6
Open Access | Times Cited: 72
Single-cell sequencing analysis related to sphingolipid metabolism guides immunotherapy and prognosis of skin cutaneous melanoma
Yantao Ding, Zhijie Zhao, Huabao Cai, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 42
The Influence of Tumor Microenvironment on Immune Escape of Melanoma
Aleksandra Simiczyjew, Ewelina Dratkiewicz, Justyna Mazurkiewicz, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8359-8359
Open Access | Times Cited: 108
Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations
Ryan C. Augustin, Greg M. Delgoffe, Yana G. Najjar
Cancers (2020) Vol. 12, Iss. 12, pp. 3802-3802
Open Access | Times Cited: 84
The Role of Ceramide Metabolism and Signaling in the Regulation of Mitophagy and Cancer Therapy
Megan A. Sheridan, Besim Öğretmen
Cancers (2021) Vol. 13, Iss. 10, pp. 2475-2475
Open Access | Times Cited: 66
Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
Dimitrios C. Ziogas, Charalampos Theocharopoulos, Tilemachos Koutouratsas, et al.
Cancer Treatment Reviews (2022) Vol. 113, pp. 102499-102499
Closed Access | Times Cited: 54
Tumor Derived Extracellular Vesicles Drive T Cell Exhaustion in Tumor Microenvironment through Sphingosine Mediated Signaling and Impacting Immunotherapy Outcomes in Ovarian Cancer
Prachi Gupta, Ishaque P. Kadamberi, Sonam Mittal, et al.
Advanced Science (2022) Vol. 9, Iss. 14
Open Access | Times Cited: 48
Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment
Alhaji H. Janneh, Besim Öğretmen
Cancers (2022) Vol. 14, Iss. 9, pp. 2183-2183
Open Access | Times Cited: 44
Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti–PD-1 Immune Checkpoint Blockade
Pierre L. Triozzi, Elizabeth R. Stirling, Qianqian Song, et al.
Clinical Cancer Research (2022) Vol. 28, Iss. 6, pp. 1192-1202
Open Access | Times Cited: 43
Immune escape and metastasis mechanisms in melanoma: breaking down the dichotomy
Carl A. Shirley, Gagan Chhabra, Deeba Amiri, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 13
Signaling controversy and future therapeutical perspectives of targeting sphingolipid network in cancer immune editing and resistance to tumor necrosis factor-α immunotherapy
Olga Sukocheva, Маргарита Е. Неганова, Yulia Aleksandrova, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 11
Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance
Anna Fateeva, Kevinn Eddy, Suzie Chen
Cancers (2024) Vol. 16, Iss. 8, pp. 1571-1571
Open Access | Times Cited: 10
Sphingosine-1-Phosphate Metabolic Pathway in Cancer: Implications for Therapeutic Targets
Miguel L. Rufail, Rosaria Bassi, Paola Giussani
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1056-1056
Open Access | Times Cited: 1
Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma
Claudia Ceci, Maria Grazia Atzori, Pedro Miguel Lacal, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3401-3401
Open Access | Times Cited: 57
Recent advances in the role of sphingosine 1‐phosphate in cancer
Nigel J. Pyne, Susan Pyne
FEBS Letters (2020) Vol. 594, Iss. 22, pp. 3583-3601
Open Access | Times Cited: 51
Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives
Laurence Pellerin, Lorry Carrié, Carine Dufau, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3147-3147
Open Access | Times Cited: 50
Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer
Kyu Sic You, Yong Weon Yi, Jeonghee Cho, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 6, pp. 589-589
Open Access | Times Cited: 46
Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma
Se Ryeong Jang, Nikita Nikita, Joshua Banks, et al.
JAMA Network Open (2021) Vol. 4, Iss. 12, pp. e2136823-e2136823
Open Access | Times Cited: 46
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
Anne Montfort, Florie Bertrand, Julia Rochotte, et al.
Cancer Immunology Research (2021) Vol. 9, Iss. 5, pp. 568-582
Open Access | Times Cited: 43
Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases
Yanhong Bu, Hong Wu, Ran Deng, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 42
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
Jordan W. Conway, Robert V. Rawson, Serigne Lo, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 9, pp. e004884-e004884
Open Access | Times Cited: 35
Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter
Jessica Thornton, Gagan Chhabra, Chandra K. Singh, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top